Nephrogenic fibrosing dermopathy medical therapy

Nephrogenic fibrosing dermopathy Microchapters
Home
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Nephrogenic fibrosing dermopathy from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Nephrogenic fibrosing dermopathy medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Nephrogenic fibrosing dermopathy medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Nephrogenic fibrosing dermopathy medical therapy
CDC on Nephrogenic fibrosing dermopathy medical therapy
Nephrogenic fibrosing dermopathy medical therapy in the news
Blogs on Nephrogenic fibrosing dermopathy medical therapy
Directions to Hospitals Treating Nephrogenic fibrosing dermopathy
Risk calculators and risk factors for Nephrogenic fibrosing dermopathy medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Medical Therapy

Most patients with NFD have undergone hemodialysis for renal failure, some have never undergone dialysis and others have received only peritoneal dialysis. Many patients have taken immunosuppressive medications and have other diseases, such as hepatitis C. Four of the five FDA-approved gadolinium contrast agents have been principally implicated in NFD, including Omniscan, Multihance, Magnevist, and OptiMARK.